Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug 2;194(29):E1041.
doi: 10.1503/cmaj.146689-l.

Benefits of nirmatrelvir-ritonavir remain unproven for some populations

Emily G McDonald  1 , Todd Lee  1
Affiliations
Comment

Benefits of nirmatrelvir-ritonavir remain unproven for some populations

Emily G McDonald et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Emily McDonald and Todd Lee report funding from the Canadian Institutes of Health Research, the Centre for Aging and Brain Health Innovation and the Canadian Frailty Network. They are the co-owners of MedSafer (a software that guides clinicians through deprescribing) and MedSafer Corp, which licenses the software. Emily McDonald also reports meeting support from the Canadian Task Force on Preventive Health Care. She is a member of the executive of WikiGuidelines, a nonprofit organization.

Comment on

  • Nirmatrelvir-ritonavir for COVID-19.
    McDonald EG, Lee TC. McDonald EG, et al. CMAJ. 2022 Feb 14;194(6):E218. doi: 10.1503/cmaj.220081. Epub 2022 Feb 3. CMAJ. 2022. PMID: 35115376 Free PMC article. No abstract available.
  • Renalism.
    Hiremath S. Hiremath S. CMAJ. 2022 Aug 2;194(29):E1040. doi: 10.1503/cmaj.146430-l. CMAJ. 2022. PMID: 35918093 Free PMC article. No abstract available.

References

    1. Hiremath S. Renalism [letter]. CMAJ 2022; 194: E1040. - PMC - PubMed
    1. McDonald EG, Lee TC. Nirmatrelvir-ritonavir for COVID-19. CMAJ 2022;194:E218. - PMC - PubMed
    1. Moryousef J, Bortolussi-Courval E, Podymow T, et al. . Deprescribing opportunities for hospitalized patients with end-stage kidney disease on hemodialysis: a secondary analysis of the MedSafer cluster randomized controlled trial. Can J Kidney Health Dis 2022;9:20543581221098778. - PMC - PubMed